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ABSTRACT
BACKGROUND: The aim of this study was to evaluate the therapeutic efficiency of Anakinra, an IL-1β antagonist with anti-inflam-
matory effects, in an experimental model of traumatic brain injury (TBI).
METHODS: Fifty-four rats underwent TBI after a weighted object was dropped onto a metal disc secured to their skulls. Animals 
were randomized into 3 main groups: control (n=18), TBI + saline (n=18; six animals per time-point) with samples obtained at the 
first, sixth and twenty-fourth h postoperatively, and TBI + Anakinra (n=18; six animals per time-point) with brain samples obtained at 
the first, sixth and twenty-fourth h postoperatively. Brain tissue and blood serum were extracted for the analysis of IL-1β, malondial-
dehyde, glutathione peroxidase, superoxide dismutase, and catalase levels. Tissue sections were evaluated histopathologically under a 
light microscope.
RESULTS: After trauma, tissue and serum IL-1β levels were significantly elevated and after Anakinra administration, these levels 
substantially decreased. Glutathione peroxidase, superoxide dismutase, and catalase activity decreased following TBI and Anakinra ad-
ministration proved effective in increasing the activity of these antioxidant enzymes. Histopathological analysis confirmed that Anakinra 
might protect the brain tissue and nerve cells from injury.
CONCLUSION: Results demonstrate that Anakinra reduces the development of inflammation and tissue injury events associated 
with TBI.
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potentially avoidable event. This secondary neuronal death is 
determined by a large number of cellular, molecular, and bio-
chemical cascades. One such cascade thought to contribute 
to the evolution of this secondary damage is the local inflam-
matory response in the injured brain tissue.[2] Microglial cells 
have been suggested to be the source of cytotoxic cytokines, 
such as tumor necrosis factor alpha (TNF-α) and interleukin 
1β (IL-1β), killing oligodendrocytes. In fact, increased synthe-
sis and/or secretion of IL-1β is detectable at the injury site 
within one h after spinal cord injury (SCI). IL-1β is a member 
of the interleukin 1 cytokine family. The gene encoding IL-1β, 
along with eight other IL-1 family genes, form a cytokine clus-
ter on chromosome 2.[3] IL-1β is produced by activated mac-
rophages as a pro-protein, which is proteolytically processed 
to its active form by caspase 1 (CASP1/ICE). This cytokine 
is an important mediator of the inflammatory response and 
involves in a variety of cellular activities, including cell prolif-
eration, differentiation, and apoptosis.[3]
  EXPERIMENTAL STUDY
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INTRODUCTION
Traumatic brain injury (TBI) immediately causes direct me-
chanical damage to the brain, referred to as the primary 
damage,[1] resulting in the immediate death of a number of 
neurons that cannot be recovered or regenerated. However, 
neurons continue to die for hours after TBI, representing a 
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IL-1 is produced in response to inflammatory stimuli and 
mediates various physiologic responses, including inflamma-
tory and immunologic reactions. Anakinra, an antagonist ex-
pressed in many tissues and organs, has been shown to com-
petitively inhibit the binding of IL-1 to the IL-1 type receptor.
[4] In patients with rheumatoid arthritis, this natural IL-1 
receptor antagonist is not found in effective concentrations 
to counteract elevated IL-1 concentrations. Thus, Kineret is 
not considered a disease-modifying anti-rheumatic drug, but 
rather a biological response modifier due to its ability to se-
lectively target the pathologic element of the disease.[5]
In the current study, the following endpoints of the inflam-
matory response were determined: histological damage; 
cytokine expression (IL-1β); measurement of lipid peroxida-
tion and oxidative stress (glutathione peroxidase, malondi-
aldehyde, and superoxide dismutase) and these various fac-
tors were used to evaluate whether Anakinra administration 
could protect brain tissue following traumatic brain injury.
MATERIALS AND METHODS
Fifty-four adult male Wistar albino rats weighing 300-350 g 
were used in this study. Animal care and all experiments were 
in accordance with the European Communities Council Di-
rective of November 24, 1986 (86/609/EEC) on the protec-
tion of animals for experimental use. All experimental pro-
cedures used in this research were approved by the ethical 
committee of the Ministry of Health, Ankara Education and 
Research Hospital.
Surgical Procedure and Sample Preparation
All rats were kept under environmentally controlled condi-
tions at 22-25°C with appropriate humidity, a 12-h light cycle, 
and free access to food and water. The surgical procedure 
was performed under general anesthesia induced by intra-
peritoneal (IP) xylazine (10 mg/kg; Bayer, Istanbul, Turkey) 
and Ketamine hydrochloride (50 mg/kg; Parke-Davis, Istanbul, 
Turkey). A rectal probe was inserted and the animals were 
positioned on a heating pad in order to ensure that their body 
temperature was maintained at 37°C. A moderate brain-in-
jury model, described by Marmarou et al. and modified by 
Ucar et al., was applied for head trauma.[6,7] Briefly, rats were 
placed in prone position and a midline incision was made on 
the head to expose the coronal and lambdoid sutures. A me-
tallic disc in 10 mm diameter and 3 mm thickness was fixed 
to the cranium using bone wax, and a lead object weighing 
450 g was allowed a free fall from a height of 70 cm through 
a copper tube onto the metal disc. The head of the animals 
was supported on a 10-cm foam bed providing confirmation 
of impact. After surgery, 1.0 cc of saline was subcutaneously 
administered to replace the blood volume lost during surgery 
and the wound was closed in layers with silk sutures. All ani-
mals were anesthetized with the above-mentioned agents at 
24 h after trauma and their brains were extracted without any 
damage. Neural tissue samples were obtained by excising the 
left frontoparietal lobes from the boundary of the interhemi-
spheric fissure and were subjected to biochemical analyses. 
The remaining parts of the brains were maintained in formal-
dehyde solution for histopathological analysis.
Experimental Groups
Rats were randomly allocated into the following 3 main groups and 
subgroups: Control: (n=18, 6 rats per time window); rats un-
derwent skin incisions only and non-traumatic brain samples 
were obtained at the first, sixth and twenty-fourth h after 
surgery.
TBI + Saline: (n=18, 6 rats per time window); rats were sub-
jected to TBI and received a single IP dose of 1 mL/kg saline. 
Traumatic brain tissue samples were obtained at the first, 
sixth and twenty-fourth h after surgery.
TBI + Anakinra: (n=18, 6 rats per time window); rats were 
subjected to TBI and received a single IP dose of Kineret 
(Anakinra, Swedish Orphan Biovitrum AB, Stockholm, Swe-
den) immediately following TBI. Traumatic brain tissue sam-
ples were then obtained at the first, sixth and twenty-fourth 
h after surgery.
Cytokine Assay
Serum and tissue IL-1β concentrations were determined us-
ing the double-antibody sandwich enzyme-linked immunosor-
bent assay (R & D systems, Minneapolis, MN, USA) according 
to the manufacturer’s instructions.
Measurement of Lipid Peroxidation and
Oxidative Stress
Glutathione Peroxidase Analysis
Glutathione peroxidase (GSH-Px) activity was measured fol-
lowing changes in NADPH absorbance at 340 nm.[8] In the 
activity calculations (IU, international unit), extinction coef-
ficients of NADPH were used for GSH-Px. Results were ex-
pressed as IU/mg protein.
Malondialdehyde Analysis
Malondialdehyde (MDA) is formed from the breakdown of 
polyunsaturated fatty acids and serves as an important and 
reliable index for determining the extent of peroxidation re-
actions.[9] Tissue MDA levels were determined by a method 
based on a reaction with thiobarbituric acid (TBA). Briefly, 
samples were mixed with two volumes of cold saline solu-
tion containing 0.001% butylated hydroxytoluene (BHT) (200 
μl of 0.01% BHT solution in methanol) and 0.07% sodium 
dodecyl sulfate (SDS) (20 μl of 7% SDS). One ml of sample 
was then added to 500 μl of 0.01 NH2SO4 and 500 μl of the 
TBA reagent (0.67% TBA in 50% acetic acid) to precipitate 
protein. Samples were heated in boiling water for 60 min, and 
after cooling, an equal volume (2 ml) of n-butanol was added 
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to each test tube and mixed. The mixture was centrifuged 
at 4,000 rpm for 10 min at room temperature. The absor-
bance of the organic layer in a 1-ml cell was read at 535 nm 
(Molecular Devices Corporation, Sunnyvale, CA, USA). MDA 
concentrations were expressed as nanomoles per milligram 
wet tissue weight.
Superoxide Dismutase Analysis 
Total superoxide dismutase (SOD) (Cu–Zn and Mn, EC 
1.15.1.1) activity was determined according to the method 
of Sun et al.[10] The principle of the method is based on the 
inhibition of nitroblue tetrazolium (NBT) reduction by the 
xanthine–xanthine oxidase system as a superoxide generator. 
Activity was assessed in the ethanol phase of the supernatant 
after 1.0 ml ethanol/chloroform mixture (5/3, v/v) was added 
to the same volume of sample and centrifuged. One unit of 
SOD was defined as the enzyme amount causing 50% inhibi-
tion in the NBT reduction rate. SOD activity was expressed 
as U/mg protein.
Catalase Analysis
Catalase (CAT) activity was determined by the method de-
scribed by Aebi.[11] The principle of CAT activity is based on 
the determination of the rate constant (k, sec-1) or of the 
hydrogen peroxide decomposition rate at 240 nm. Results 
were expressed as kU/g of protein.
Histopathological Procedures
For histological examination, brain tissue samples were 
fixed at 10% neutral buffered formalin, dehydrated through 
a graded series of ethanol and embedded in paraffin. 5μm 
thick sections stained with hematoxylin-eosin were analyzed 
and photographed with light microscopy (Olympus CX21, 
Olympus America Inc., Melville, NY, USA). In all groups, a 
semi quantitative scoring system, ranging between 0 and 3, 
was used for grading both histopathological changes (vascular 
congestion, PMNL infiltration, gliosis/satellitosis and spongio-
sis) and neuronal degeneration signs (cytoplasmic eosinophil-
ia and nuclear pyknosis) in the brain tissues of each animal. 
Histopathological changes were evaluated by two observers 
blinded to the groups and scored as follows: 0: absent; 1: 
mild; 2: moderate; 3: common. Histopathological scores for 
each group was calculated averaging the scores of each animal 
in groups.[12]
Statistical Analysis
Data were analyzed using the Statistical Package for Social 
Sciences (SPSS) software version 19.0 for Windows (SPSS 
Inc., Chicago, IL). Non-parametric tests were applied and the 
Mann-Whitney U test was used to compare two independent 
groups while the Kruskal-Wallis test was used to compare 
more than two groups. The Wilcoxon Signed Ranks Test was 
used to compare two dependent groups while the Friedman 
Test was used to compare more than two groups. Bonferroni 
correction for multiple tests was used for post-hoc compari-
sons. All differences associated with a chance probability of 
0.05 or less were considered statistically significant. Continu-
ous variables were presented as mean±SD.
RESULTS
Tissue and Serum IL-1β Analysis
Table 1 summarizes the changes in tissue and serum levels 
of IL-1β. Mean tissue and serum level of IL-1β were the 
same although tissue and serum samples were obtained at 
different time periods. There were statistically significant 
differences between the trauma (177.24±6.24 pg/ml), con-
trol (213.17±36.57 pg/ml), and Anakinra (94.8 4±24.45 pg/
ml) groups at the first h after trauma with regard to mean 
tissue IL-1β activity (p=0.001). After the sixth h, increased 
tissue IL-1β activity in trauma- and Anakinra-treated groups 
was shown at 180.86±5.89 pg/ml and 137.90±65.02 pg/ml, 
respectively. There was also a statistically significant differ-
ence determined between the groups (p=0.001). Trauma 
(214.78±45.06 pg/ml), control (213.17±36.57 pg/ml), and 
Anakinra (201.42±39.32 pg/ml) groups were compared at 
the twenty-fourth h after trauma with regard to mean tis-
sue IL-1β activity and no statistically significant difference 
was found (p=0.149), even though tissue levels of IL-1β in 
Anakinra-treated groups continued to decline. There were, 
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Table 1. Summarizing IL-1β changes in the tissue and serum 
Variables (tissue) Control group Trauma group Anakinra group p
1 h IL-1β (pg/ml) 213.17±36.57 177.24±6.26 94.84±24.45 0.001
6 h IL-1β1  80.86±5.39 137.90±65.02 0.001
24 h IL-1β  214.78±45.06 201.42±39.32 0.149
Variables (serum) Control group Trauma group Anakinra group p
1 h IL-1β (pg/ml) 57.42±4.14 50.14±10.65 70.91±1.90 0.005
6 h IL-1β  37.51±4.12 154.56±55.70 0.001
Values are expressed as mean±SD or median (IQR), where applicable. IL: Interleukin.
however, statistically significant differences between trauma 
(50.15±4.88 pg/ml), control (60.05±2.19 pg/ml) and Anakinra-
treated (52.25±2.01 pg/ml) groups one h after trauma with 
regard to mean serum IL-1β activity (p=0.003). Additionally, 
six h after trauma, a statistically significant increase (p=0.001) 
in serum IL-1β activity was observed in the Anakinra-treated 
group (154.56±55.70 pg/ml).
Tissue and Serum MDA Analysis
Mean tissue MDA levels in the trauma group were 7.16±1.02 
nmol/mg, 11.66±2.94 nmol/mg, and 15.95±02.98 nmol/mg at 
the first, sixth and twenty-fourth h, respectively. Mean tis-
sue levels in the Anakinra group were 7.20±4.39 nmol/mg, 
11.46±4.00 nmol/mg, and 9.37±4.44 nmol/mg at the first, sixth 
and twenty-fourth h after trauma, respectively. A statistically 
significant difference was observed when mean serum MDA 
levels in trauma and Anakinra groups were compared with 
the control group (10.25±2.12 nmol/mg) at all time points 
(p=0.008). Mean serum MDA levels in the trauma groups 
were 0.10±0.04 nmol/mg and 0.07±0.04 nmol/mg at the first 
and sixth h, respectively. Mean tissue levels in the Anakinra 
group were 0.04±0.01 nmol/mg and 0.05±0.01 nmol/mg at 
the fist and sixth h after trauma, respectively. A statistically 
significant difference was seen when mean serum MDA levels 
in trauma and Anakinra groups were compared with the con-
trol group (0.04±0.01 nmol/mg) at all time-points (p=0.005) 
(Table 2).
Tissue and Serum GPx Analysis
Mean tissue GPx levels at the first h following trauma for 
trauma (0.28±0.12 IU/mg), control (0.27±0.11 IU/mg), and 
Anakinra groups (0.21±0.25 IU/mg) were not significantly dif-
ferent (p=0.899). Six hours following TBI, mean tissue GPx 
levels were 0.25±0.12 IU/mg in the trauma groups, 0.41±0.33 
IU/mg in the Anakinra groups, and 0.27±0.11 IU/mg in the 
control group; there were no statistically significant differenc-
es between groups at this time-point (p=0.05). After twenty-
four h, mean tissue GPx continued to decline in the Anakinra-
treated group (0.31±0.19 IU/mg), but this reduction was not 
determined to be statistically significant (p=0.189). Mean se-
rum GPx levels in trauma groups were 0.0041±0.0007 IU/mg 
and 0.0033±0.002 IU/mg at the first and sixth h, respectively. 
The mean serum GPx levels in the Anakinra group were 
0.0029±0.0011 IU/mg and 0.001±0.00 IU/mg at the first and 
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Table 2. Biochemical alterations in the tissue and serum among groups
Variables (tissue) Control Trauma Anakinra p
1 h MDA (nmol/mg) 10.25±2.12 7.16±1.02 7.20±4.39 0.008
6 h MDA 10.25±2.12 11.66±2.95 11.46±4.00 0.567
24 h MDA 10.25±2.12 15.95±2.98 9.37±4.44 0.008
1 h GPx (IU/mg) 0.27±0.11 0.28±0.12 0.21±0.25 0.899
6 h GPx 0.27±0.11 0.25±0.12 0.41±0.33 0.049
24 h GPx 0.27±0.11 0.39±0.13 0.31±0.14 0.189
1 h SOD (U/mg) 14.51±1.74 10.05±0.52 7.63±1.84 0.001
6 h SOD 14.51±1.74 17.82±1.21 10.14±4.00 0.003
24 h SOD 14.51±1.74 19.92±4.25 13.46±1.46 0.144
1 h CAT (IU/mg) 3.48±0.91 4.67±1.69 10.63±3.55 0.001
6 h CAT 3.48±0.91 4.06±0.47 4.83±1.07 0.007
24 h CAT 3.48±0.91 7.11±1.85 1.95±0.11 0.004
Variables (serum) Control Trauma Anakinra p
1 h MDA (nmol/mg) 0.04±0.01 0.10±0.04 0.04±0.01 0.004
6 h MDA 0.04±0.01 0.07±0.04 0.05±0.01 0.005
1 h GPx (IU/mg) 0.003±0.001 0.004±0.007 0.002±0.001 0.061
6 h GPx 0.003±0.001 0.005±0.002 0.002±0.001 0.003
1 h SOD (U/mg) 0.06±0.01 0.08±0.02 0.05±0.03 0.064
6 h SOD 0.06±0.01 0.06±0.01 0.06±0.03 0.805
1 h CAT (IU/mg) 0.28±0.06 0.52±0.12 0.30±0.09 0.003
6 h CAT 0.28±0.06 0.16±0.07 0.30±0.22 0.008
All values are expressed as mean±SD or median (IQR), where applicable.
CAT: Catalase; GPx: Glutathione peroxidase; MDA: Malondialdehyde; SOD: Superoxide dismutase.
sixth h following TBI, respectively. A statistically significant 
difference was observed in mean serum GPx levels when the 
trauma and Anakinra groups were compared to the control 
group (0.0032±0.0013 IU/mg) at all time-points (p=0.003). 
However, there was no statistically significant difference 
in serum GPx levels between the three time-points of the 
Anakinra-treated groups (p=0.513) (Table 2).
Tissue and Serum Superoxide Dismutase Analysis
Mean tissue SOD levels in the trauma groups were 10.05±0.52 
U/mg, 17.82±7.11 U/mg, and 19.92 ± 4.25 nmol/mg at the 
first, sixth, and twenty-fourth h, respectively. The mean tis-
sue SOD levels in the Anakinra group were 7.63±1.84 U/mg, 
10.14±4.00 U/mg, and 13.46±1.46 U/mg at the first, sixth, 
and twenty-fourth h after trauma, respectively. Mean tissue 
SOD levels of the trauma and Anakinra groups were then 
compared with those of the control group (14.51±2.74 U/
mg) and a statistically significant difference was found at all 
time-points (p=0.003). Mean serum SOD levels in the con-
trol group were 0.08±0.02 U/mg and 0.08±0.01 U/mg at the 
first and sixth h after sham surgery, respectively. Mean serum 
SOD levels in the Anakinra group were 0.05±0.03 U/mg and 
0.06±0.03 U/mg at the first and sixth h after trauma, respec-
tively. When mean tissue SOD levels in trauma and Anakinra 
groups were compared with the control group (0.06±0.01 
U/mg), no statistically significant differences were found be-
tween groups at any of the time-points (p=0.805) (Table 2).
Tissue and Serum Catalase Analysis
Mean tissue CAT levels in the trauma group were 4.67±1.69 
IU/mg, 4.06±0.47 IU/mg, and 7.11±1.85 IU/mg at the first, 
sixth, and twenty-fourth h, respectively. Mean tissue CAT lev-
els in the Anakinra group were 10.63±3.55 IU/mg, 4.83±1.07 
IU/mg, and 1.95±0.11 IU/mg 1, 6, and 24 h after trauma, re-
spectively. When mean tissue CAT levels in the trauma and 
Anakinra groups were compared with the control group 
(3.48±0.91 IU/mg), a statistically significant difference was 
found between groups at all time-points (p=0.004). Mean 
serum CAT levels in the trauma group were 0.52±0.12 IU/
mg and 0.16±0.07 IU/mg at the first and sixth h, respectively. 
Mean serum CAT levels in the Anakinra group were 0.30±0.09 
IU/mg and 0.30±0.26 IU/mg at the first and sixth h after trau-
ma, respectively. No statistically significant difference was 
observed when CAT levels in the Anakinra group were com-
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(c)
(b)
(d)
Figure 1. Photomicrograph of the control and trauma groups (a) Control group: The parenchymal features of the cor-
tex morphology appeared normal, P: Piamater, Stars: neurophil, Arrowheads: neurons, Arrows: blood vessels, x10, 
Bar:50 µm; (b-d) Trauma 1,6,24 hours, Stars: edema in neurophil, Arrows: blood vessels with perivascular astrocytic 
foot process swelling x10, Bar: 50 µm, inlets: Arrowheads: pyramidal neurons showing cytoplasmic eosinophilia and 
pyknotic nucleus with perineural satellitosis and cleared areas formed by swollen astrocytic extensions, x40, Bar: 20 
µm, Hematoxylin-eosin staining.
pared to serum levels in the control group (0.28±0.06 IU/mg) 
at any of the time-points (p=0.56) (Table 2).
Histopathological Assessment
All rats of the control group showed no nerve tissue damage 
in the brain cortex. Neurons and neuroglia cells had normal 
morphologic features (Fig. 1a). In the first, sixth and twenty-
fourth h trauma groups, cortical neurons showed cytoplas-
mic eosinophilia so called eosinophilic neuron and pyknotic 
nucleus with no discernible nucleolus. Perineural satellitosis 
accumulating of more than one glia cell around eosinophilic 
neurons were also observed. The perineural and perivascular 
spaces were prominent due to the swelling of astrocytic foot 
processes. In addition, blood vessels showed congestion and 
stasis. The fibrillary matrix of the cerebral cortex (neurophil) 
showed spongiosis due to the edema of cellular extensions 
of the neurons and glia cells (Fig. 1b-d). In the Anakinra ap-
plied groups, first, sixth and twenty-fourth h after trauma also 
showed same signs of damage of nerve tissue including neu-
rons and neurophil of the brain cortex (Figs. 2a-f ). Neuronal 
degeneration (eosinophilic neurons with pyknotic nucleus) 
and satellitosis scores of the Anakinra groups were found to 
be better than trauma groups at the sixth and twenty-fourth 
h. Moreover, vascular congestion scores were determined to 
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Table 3. Mean values of histopathological score distribution among groups after traumatic brain injury 
 Control Trauma Trauma Trauma Anakinra Anakinra Anakinra
  1 hour 6 hour 24 hour 1 hour 6 hour 24 hour
Neuronal degeneration
(cytoplasmic eosinophilia -red neuron-, pyknosis) 0 1.6 2.5 3 2.8 2.1 2.8
Gliosis/satellitosis 0 1.8 2.85 3 1.45 2.3 2.45
Spongiosis 0 1.4 2.16 3 2.3 2.6 2.6
PMNL Infiltration 0 0 0 0 0 0 0
Vascular congestion 0 1.6 2.5 3 0.3 1.3 1.3
0-3 (0: absent, 1: mild, 2: moderate, 3: common).
Figure 2. Photomicrograph of brain sections from the Anakinra-treated group 1 h after trauma (a) Arrow: Gliosis around blood vessels; 
Star: neurophil, x10, Bar: 50 µm inlets: Arrowhead: Satellitosis; Wavy arrow: eosinophilic neuron; Arrow: microglia x40, Bar: 20 µm (b) 
Stars: vacuolization and edema in neurophil; Wavy arrows: neurons with eosinophilic cytoplasm and pyknotic nucleus, x40, Bar: 20 µm, 
Hematoxylin-eosin staining. Photomicrograph of a brain section from the Anakinra-treated group 6 h after trauma (c) Proliferation of glial 
cells between injured neurons, x40, Bar: 20 µm (d) Arrowheads: perineural satellitosis; Wavy arrows: numerous neurons with eosinophilic 
cytoplasm and pyknotic nucleus, x40, Bar: 20 µm, Hematoxylin-eosin staining. Photomicrograph of the Anakinra-treated group 24 h after 
trauma, (e, f) Arrowheads: perineural satellitosis; Wavy arrows: neurons with eosinophilic cytoplasm and pyknotic nucleus, x40, Bar: 20 
µm, Hematoxylin-eosin staining.
(a)
(d)
(b)
(e)
(c)
(f)
be lower than the trauma groups at all time points and PMNL 
infiltration was not seen in trauma and Anakinra groups at all 
time points (Table 3).
DISCUSSION
Neuronal damage is thought to continue for several days af-
ter the initial ischemia expansion occurring within the first 24 
h of TBI.[13] The expression of proinflammatory cytokines at 
the site of injury, including IL-1β and TNF-α, regulate precise 
cellular events that occur within the first few hours of TBI and 
persist in the neural tissue for several days with cytokines also 
being detectable on microglia, perivascular macrophages, and 
astrocytes.[14,15] Most important secondary factors leading to 
further neuronal death are lipid peroxidation, apoptosis, and 
development of reactive oxygen species.[16-20] In our study, 
cellular and biochemical changes were observed in order to 
assess the actual outcome of TBI in relation to short-term 
histological damage and cytokine expression. Fassbender et 
al. have analyzed trauma-induced release of IL-1β in brain 
tissue perfusates and reported that IL-1β was unexpectedly 
detected within 60 min of injury. Moreover, extracellularly se-
creted IL-1β protein was found to gradually increase, peaking 
at day two, and decrease thereafter. Therefore, IL-1β release 
may represent a precondition for the orchestrating role of 
this mediator in the inflammatory response cascade.[21] In this 
study, we also demonstrated that serum and tissue levels of 
IL-1β were elevated at the sixth h after TBI. As shown in our 
results, Anakinra was found to be more effective in reducing 
tissue levels of IL-1β in the first h after trauma. This finding is 
not surprising since the release of IL-1β in brain tissue occurs 
within less than one h of trauma. Rothwell et al. have shown 
that neuronal inflammation, inducing pro-cytokine IL-1β, 
plays a key role in this process involving glial cells as well as in-
vading immune cells. Moreover, induced cytokines have been 
suggested to indicate the extent of central nervous system in-
jury.[14,22] In the present study, morphological features relevant 
with neuronal injury and higher histopathological scores fol-
lowing brain trauma in rats were demonstrated. In contrast, 
administration of Anakinra led to an improvement of nerve 
tissue and cell morphology after TBI through a reduction in 
oxidative stress. Furthermore, this amelioration was revealed 
to be associated with decreased tissue and serum levels of 
IL-1β. On the contrary, no significant reduction in MDA was 
observed, indicating a lack of lipid peroxidation inhibition 
in brain sections and serum levels obtained from Anakinra-
treated rats. This observation is in disagreement with a study 
conducted by Marini et al. demonstrating that inhibition of 
lipid peroxidation has reduced IL-1β expression and pro-
tected neuronal tissue from damage.[20] Finally, the evalua-
tion with light microscopy showed that the histopathological 
damage scores of neuronal degeneration, satellitosis, vascular 
congestion and spongiosis were reduced in rats treated with 
Anakinra at the twenty-fourth h after TBI. The findings of the 
current study suggested that IL-1β played a detrimental role 
in the development and severity of post-traumatic injury and 
that this damaging effect could be attenuated by blocking this 
cytokine’s signaling pathway.
Treatment with Anakinra inhibits IL-1β and protects the brain 
tissue and neuronal cells from damage in TBI. However, a 
few of the possible mechanisms by which Anakinra attenu-
ates neurological injury were demonstrated in this study and 
a better understanding of the mechanisms of Anakinra might 
lead to future clinical strategies aimed at treating TBI.
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OLGU SUNUMU
İnterlökin 1-beta inhibitörü Anakinra’nın sıçanlarda travmatik
beyin hasarına karşı terapötik etkinliğinin değerlendirmesi
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AMAÇ: Bu çalışmanın amacı, deneysel travmatik beyin hasarı (TBH) modelinde interlökin 1 beta (IL-1β) inhibitörü Anakinra’nın tedavi edici etkin-
liğinin değerlendirilmesidir.
GEREÇ VE YÖNTEM: Elli dört Wistar albino sıçana anestezi uygulaması sonrası kafatası üzerine konan bir metal disk üzerine 2 metreden 450 g 
ağırlık düşürülerek deneysel kapalı kafa travması oluşturuldu. Hayvanlar üç ana gruba ayrıldı: Kontrol (n=18), TBH + salin (n=18; zaman başına altı 
hayvan) numuneler bir, altı ve 24 saat sonra alındı ve TBH + Anakinra (n=18; zaman başına altı hayvan) numuneler bir, altı ve 24 saat sonra alındı. IL-
1β, malondialdehit, glutatyon peroksidaz, süperoksit dismutaz ve katalaz düzeylerinin analizi için beyin dokusu ve kan örnekleri alındı. Doku kesitleri 
histopatolojik olarak ışık mikroskobunda değerlendirildi.
BULGULAR: Travma sonrası, doku ve serum IL-1β düzeyleri önemli ölçüde artmıştı ve bu düzeyler Anakinra verilmesinden sonra azaldı. TBH taki-
ben glutatyon peroksidaz, süperoksit dismutaz ve katalaz aktivitesi azalmış ve Anakinra uygulanması bu antioksidan enzimlerin aktivitesini artırmada 
etkili olmuştur. Histopatolojik analiz Anakinra’nın beyin dokusu ve sinir hücrelerini travmadan koruyabileğini doğrulamıştır.
TARTIŞMA: Anakinra’nın TBH ile ortaya çıkan enflamasyon ve doku hasarı gelişimini azalttığını göstermektedir.
Anahtar sözcükler: Anakinra; antioksidan; interlökin-1; nöroproteksiyon; travmatik beyin hasarı.
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